Revvity Inc (RVTY) 2017 Q3 法說會逐字稿

Good day, ladies and gentlemen, and welcome to the Q3 2017 PerkinElmer Earnings Conference Call. (Operator Instructions) As a reminder, this call may be recorded.

I would now like to introduce your host for today's conference, Tommy Thomas, Vice President of Investor Relations. Sir, you may begin.

Thank you, Heather. Good afternoon, and welcome to PerkinElmer Third Quarter 2017 Earnings Conference Call. With me on the call are Rob Friel, Chairman and Chief Executive Officer; and Andy Wilson, Senior Vice President and Chief Financial Officer.

If you have not received a copy our earnings press release, you may get one from the Investors section of our website at www.perkinelmer.com. Please note that this call is being webcast live and will be archived on our website until November 16, 2017.

Before we begin, we need to remind everyone of the safe harbor statements that we have outlined in our earnings press release issued earlier this afternoon and also those in our SEC filings. Any forward-looking statements made today represent our views only as of today. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. So you should not rely on any of today's forward-looking statements as representing our views as of any date after today.

During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures we plan to use during this call to the most directly comparable GAAP measure is available as an attachment to our earnings press release. To the extent we use non-GAAP financial measures during this call that are not reconciled to GAAP in the attachment, we will provide reconciliations promptly.

I'm now pleased to introduce the chairman and Chief Executive Officer of PerkinElmer, Rob Friel.

Rob?

Thanks, Tommy. Good afternoon, and thank you for joining us today. I'm very pleased with our performance in the third quarter as PerkinElmer delivered revenue and EPS at the high end of our previously communicated guidance range, and we continue to make excellent progress on our strategic priorities. Similar to previous quarters, I will briefly review our financial results, discuss overall market conditions and update you on our progress during the third quarter relative to our strategic priorities, while Andy will discuss our financial results and future guidance in more detail.

Turning to our financial results. We generated revenue of $550 million during the third quarter, which represents growth of 8% over Q3 last year on a reported basis and 5% growth organically. Adjusted operating margins expanded by 30 basis points to 19.3% and adjusted earnings per share was $0.73, representing growth of 14% over Q3 last year.

Year-to-date, our financial results are tracking favorably to our original guidance in the beginning of the year. And based on our fourth quarter guidance, we are on track to exceed our full year guidance communicated back in January for both the top and bottom lines, delivering organic revenue growth of 4% and increasing adjusted earnings per share by low double digits.

Markets continue to be favorable. For the first time in over 5 years, during the third quarter we experienced positive organic growth in every region of the world and every end market in which we operate. Looking specifically at our end markets, pharma/biotech grew mid-single digits as strength in service and high-content imaging was offset from continuing headwinds in our radio nucleotide business. Diagnostics also grew mid-single digits as emerging markets continued to outpace developed markets.

Our food business was very strong, growing over 20% due to several key customer wins and the strong performance from recently introduced new products. Both environmental and industrial markets grew low single digits as environmentalists continuing to see strong growth in Asia, positive results in Americas, offset by decline in revenue in Europe. Our sales to academic customers also grew low single digits and recovered from a slow start to the year as funding outside the U.S. has improved.

Turning now to our performance against our strategic initiatives. Within Diagnostics, we continue to make good progress strengthening our core areas while expanding our addressable markets. In Q3, we launched our new mass spec platform, QSight, for the clinical market and have received a very positive response from our customers. During the third quarter, QSight was registered as a Class I instrument with the FDA. In addition, we have completed CE marking for the European market, enabling the instrument to be used in clinical applications beyond newborn screening, and we are diligently working to extend our existing and new clinical assays on QSight.

Moreover, our Diagnostics portfolio continues to address the escalating demand for greater access to quality health care across emerging regions. The performance in our Tulip Indian Diagnostics business is encouraging on both the top and bottom lines as we expand Tulip's in-vitro diagnostics offerings throughout India. These solutions add in the prevention, screening and diagnosis of communicable diseases, such as malaria, HIV and hepatitis, which are critical issues in that part of the world.

Turning briefly to our cord blood and cord tissue banking business, you may have seen earlier this year the announcement of newly published research that shows encouraging developments related to the use of a child's own cord blood to treat cerebral palsy. The Phase II clinical trial led by Duke University and with participation from some of our ViaCord families, will hopefully drive greater awareness around the potential of cord blood and cord tissue by helping further penetrate this market over time.

We also continue to make good progress on the key growth initiatives for our Diagnostic business that I've discussed previously and thought I would provide a quick update. As I've mentioned before, Vanadis is our solution for prenatal screening that leverages high-precision imaging in an automated platform enabling a much more efficient and less-expensive option versus current NGS-based NIPT testing alternatives. In the last month, we have submitted an article with data demonstrating its performance, which should be published before year-end, and we expect another article to be submitted before year-end. One research system has been installed in Europe and another will be installed shortly. These units will continue to generate more data on the Vanadis platform as we continue to validate the assay. Today, the results look very encouraging and compares very well to the current commercial NGS alternatives. As a result, we continue to be very enthusiastic about the potential for Vanadis and remain confident that our commercial launch date for the first half next year will be met.

Our PerkinElmer Genetics offering of whole genome sequencing services has begun testing samples, and we have already signed a number of contracts with both academic institutions and rare disease pharma companies. During the third quarter, we also announced our collaboration with In-Depth Genomics, or IDG. PerkinElmer Genetics is supporting IDG's program, which brings genetic diagnosis to patients across a wide range of neurological conditions. We will provide clinical whole genome sequencing, interpretation services and diagnostic reporting to IDG, and IDG will then use the de-identified genomic and clinical data to support their R&D, generating a better understanding of the cause of hundreds of rare diseases. We continue to be excited about our pipeline of opportunities as we focus these capabilities around our reproductive health business and rare diseases.

And finally, one of our major priorities for the remainder of the year is the closing of our acquisition of EUROIMMUN, which will augment our immunodiagnostic offerings with autoimmune and allergy testing. Over the past few months, we've made great progress working towards disclosing, and we have also used this period to facilitate collaborative discussions between employees of both companies to explore future opportunities. It has been an exciting time, and we are very much looking forward to uniting as one organization. The only remaining hurdle is regulatory approval in China, and we are still planning for a Q4 closing. As currently, our commitment for EUROIMMUN's minority shareholders continues until the end of this year, if we determine this is unlikely to occur, we will either purchase those shares outright or simply extend the timing of the shareholder commitments. I look forward to communicating the closing as soon as it happens, and after spending time with leaders and employees at EUROIMMUN, I am evermore encouraged by the opportunities presented by this combination.

Moving to the DAS business, which was created about 1 year ago, we've undertaken a number of significant actions to achieve our objective of accelerating profitable growth by disproportionately investing in the most attractive market opportunity, while continuing to improve commercial execution. Year-to-date, we have launched 11 new imaging and detection instruments, which are generating significant interest among customers across the environmental, food, industrial and life science research markets. Several more are still in development and slated to launch over the next couple of months.

Looking specifically at our food franchise, which is focused on adulteration, quality and safety testing capabilities, we continue developing new innovations while also seeking to acquire attractive assets to expand our $200 million plus food portfolio. During the quarter, we won a number of large tenders spanning the U.S., Australia, Europe and China that reflect the high demand for unique applications, utilizing Perkin and Delta technologies. These include whole grain analysis, the establishment of product quality grading based on sugar content, and the measurement of food fermentation for textile production, just to cite a few.

On the services side, our OneSource business continues to win competitive tenders with key pharma customers due to the breadth of our offerings, which range from asset management to scientific services and lab location. A strong indication of the phase the market has in our offering was evidenced by a recent significant win, which represents the largest initial contract in the history of OneSource.

Also during the third quarter, we have initiated the implementation of new technology-based solutions to improve our customers' experience and provide additional insights into their lab operations as well as facilitate our ability to expand in the higher-margin service offerings. From an operational execution standpoint, we are making good progress on the third component of our strategy, which is focused on continually improving our operational execution and strengthening our margin profile. In particular, our utilization of lean manufacturing methods has resulted in a 13% reduction in our manufacturing floor space globally since the end of 2015. In addition, during the same time frame, material costs have been reduced as a percentage of revenue by 700 basis points to 24% of total cost of sales. Through these initiatives and others, we remain confident in our ability to improve product gross margin significantly over the next several years.

Also, I recently attended the opening of an important expansion of our Chinese manufacturing facility to broaden our capabilities to produce several of our DAS product families. By better aligning our manufacturing footprint with the location of our customers, we should facilitate future growth in this important area of the world. These operational improvements as well as our ability to leverage our SG&A costs have enabled us to make additional investments in R&D in 2017, which we believe will translate into increased revenue from new products in 2018 and beyond. Relative to last year, investments in research and development have increased 12% or 40 basis points as a percentage of revenue, enabling us to accelerate our R&D innovations for solutions and serve higher growth markets.

So to summarize, during the quarter we continued to meet or exceed our financial commitments. However, more importantly, the combination of the successful execution of our strategic growth initiatives, favorable market conditions and the opportunities afforded by the upcoming EUROIMMUN acquisition, reinforces our belief that the growth of both our top and bottom line should accelerate in 2018 and beyond.

I'd now like to turn the call over to Andy.

Thanks, Rob. And good afternoon, everyone. Consistent with previous quarters, I'll provide some additional color on our end markets, the financial summary of our third quarter and first 9 months 2017 as well as details around our guidance for the fourth quarter.

We are pleased with our continued performance in the third quarter as adjusted revenues from continuing operations grew 8% to $555 million. Foreign exchange represented a tailwind of approximately 100 basis points with acquisitions adding approximately 200 basis points resulting in an organic growth of approximately 5%.

By business, Diagnostics, representing 30% of total sales, grew 5% organically, both in the third quarter and year-to-date, driven by growth in our emerging market diagnostic offerings and sales of our advanced genomic solutions. Discovery & Analytical Solutions representing 70% of total sales, grew 4% organically in the third quarter and 3% on a year-to-date basis, driven by new product introductions and an improving macro environment. I'll provide some additional color on both businesses in a moment.

We experienced healthy growth across all major geographies with high single-digit organic revenue growth in Asia, mid-single-digit organic revenue growth in the Americas and low single-digit organic revenue growth in Europe. In the BRIC regions, we continued to experience strong and broad-based organic revenue growth with continued double-digit organic revenue growth in China.

As to our operating results, third quarter adjusted operating margins expanded 30 basis points to 19.3%, driven by continued SG&A leverage partially offset by increased R&D investment in the quarter and year-to-date. Adjusted operating margins have expanded over 40 basis points year-to-date. As a result, adjusted earnings per share from continuing operations for the third quarter of 2017 was $0.73, a 14% increase versus the prior year and at the high end of our guidance range. Year to date, our adjusted earnings per share has increased approximately 10% in spite of a 12% increase in R&D investments, which I will talk about more shortly.

Looking further into the key drivers within our business segments for the third quarter, let's start with Diagnostics. Third quarter results were in line with our expectations, driven by strength in our advanced genomics, Perten sample prep business in the Americas and our emerging market diagnostic offerings, which continued to outperform.

Our clinical labs had another strong quarter of growth as they continued to gain traction addressing customers' needs, while our Tulip business, serving the Indian market, continues to exceed expectations.

As mentioned earlier, we continue to ramp R&D spending, which has increased on a year-to-date basis, driven by investments in both businesses. Within Diagnostics, investment spending continues to be focused on Vanadis Smart NIPT and our new mass spec for newborn screening. We're pleased to report this newborn screening tool was well received at the recent Association of Public Health Labs conference and is set for a fourth quarter launch. While as Rob mentioned, Vanadis, our innovative NIPT solution, continues to track to internal plans with data we recently submitted for publication.

Switching to our Discovery & Analytical Solutions business. Third quarter results often played out as expected and were once again driven by very strong growth in our key focus areas of food and pharma/biotech services as well as strength in the environmental offerings, while revenues from industrial and academic and government grew low single digits.

Looking at key products, growth continues to be driven by our new ICP-MS for food and environmental applications, while very strong overall growth in food was driven by Perten and pharma/biotech results were once again driven by a solid OneSource performance.

We are very pleased that our OneSource team continues to drive industry-leading growth with an expansion of services into existing customers coupled with a number of significant new customer wins year-to-date. We now believe that double-digit growth OneSource has experienced in recent quarters will be sustainable for the near to intermediate term. In terms of increased R&D spend with -- and DAS, we have been focused on developing new products targeting inorganic applications and have secured a number of wins with recent launches in ICP-OES and ICP-MS product lines.

We are also excited to be taking a new version of our newly launched gas chromatograph, an imaging instrument that should help drive organic growth acceleration in 2018.

Looking below the line, adjusted net interest and other expense for the third quarter was approximately $11 million, tracking in line with our initial guidance. And while our year-to-date adjusted tax rate is approximately 17%, slightly below our January guidance, we expect the full year tax rate to be approximately 17.5%.

Turning to the balance sheet. We finished the quarter with approximately $1.1 billion of debt and $709 million of cash, and we exit the quarter with a net debt to adjusted EBITDA ratio of approximately 0.9x. As we have previously mentioned, we expect to use a combination of cash and incremental debt to fund the acquisition of EUROIMMUN. We will communicate these details upon closing.

Turning to cash flow. Year-to-date operating cash flow from continuing operations was $165 million. And as we look ahead to the balance of 2017, we believe that we will continue to efficiently manage our working capital requirements and drive approximately $300 million of adjusted free cash flow for the year.

Looking to the fourth quarter of 2017, we believe we are well positioned to deliver a solid finish to the year. For the fourth quarter, we are forecasting reported revenues to be in the range of $613 million to $618 million, which represents organic revenue growth of approximately 4% to 5% and adjusted earnings per share are expected to be in the range of $0.93 to $0.95. As Rob mentioned, this represents organic revenue growth of approximately 4% for the year and full year earnings per share growth of 11% at the midpoint of the updated adjusted EPS range of $2.87 to $2.89.

This concludes my prepared remarks. Heather, at this time, we'd like to open up the call for questions.

(Operator Instructions) Your first question comes from William March with Janney.

First question, could you maybe just talk a little bit about the whole genome sequencing business that you just launched specifically? Who are your target customers for this product? Are there some cross-selling opportunities with the existing diagnostic portfolio? And then maybe just the margin profile of this business versus the core Diagnostic business?

Yes, sure. So it's targeted at 3 customers. First of all, our reproductive health area, and in that area, I think there is a lot of cross-selling opportunity. So I think as we talked about last quarter, our newborn screening business very often is reflexed into NGS for confirmatory testing. So one of the things we're doing is we're now doing some of the confirmatory testing with our newborn screening customers. The other area where we see good synergies with our reproductive health business is in the ViaCord area, where we have some 350,000 cords that are stored and, of course, ongoing business, where we see interest, very often, where those customers would like to have some whole genome sequencing done. So I would say that's the first area that we're focused on. The second area was the one that I mentioned in the prepared remarks where we're doing work with IDG, and they're having us do some whole genome sequencing with regard to neurological disorders. And then the third area I would mention would be in the pharmaceutical area, particularly in the orphan drug, where we're working with several pharmaceutical companies to help them particularly identify potential patients for clinical studies. So I would say that's the initial focus of the business. We're seeing early days with good uptake. And while it's a startup right now, we do anticipate as we get to higher volume that we can get to operating margins equal to or maybe even a little bit better than the company average.

Got it. And then maybe just if you could talk a little bit more about what you're seeing geographically in terms of -- I know you had a difficult comp last quarter in Asia, or whether that high single -- or low double digits we saw this quarter that was a tough comp or just kind of more commentary on what you're seeing on each of the 3 geographies?

So as I mentioned before, this was one of the first quarters in a while where we actually experienced growth in all 3 regions, so whether it's the Americas, EMEA or APAC. And so if I look at each of those, I think the U.S., we continue to see generally pretty good growth across all areas with maybe the exception of academia was a little light. But other than that, we see good growth in Diagnostics. So I would say that if you look at newborn, first of all, while births now have sort of more flat in the U.S. I would say, prior to this quarter, we actually saw them down a little bit. We think now at the end of the third quarter, if you look on a trailing 12-month basis, it's more sort of flat. But our ability to continue to expand the menu and expand what we do, also mentioned the genetic testing business that we're now seeing good growth on the Diagnostic side. Pharma continues to do well, and the environmental and safety area. So I think good demand within the Americas. I think when you look at Europe again, probably not as strong as the U.S., but good strength on the pharma aside. I would say, we saw a pick up on the industrial markets in Europe, and food was very strong. And then, of course, the highest growth area for us was in APAC, obviously, led by China. China was up sort of mid-teens for us. And that was pretty strong across the board with possibly the exception of industrial. And that was really more of a comp issue. I think last year if you looked at China, our industrial business was up high teens. So as I sort of mentioned in my prepared remarks, we're seeing pretty good strength, again, across the globe and across all the application areas.

Your next question comes from Dan Arias with Citi.

Rob, on Vanadis, as you guys get ready for commercialization there, can you just talk about how broadly you're thinking that will be in Europe? Is it going to be a meter rollout next year? Or should we kind of think about U.K., France, Germany all seeing availability fairly quickly?

Yes. I think, as you mentioned, it'll be Europe first. I think it will be somewhat metered by the tenders. And that's one of the things we're looking at relative to the potential for revenue in 2018, and we want to try and time that at least as best we can to some of the tenders in some of these countries. So I think initially, if you look at 2018, that will be a large determinant to how quickly it gets ramped up in the market. But again the intention would be to be pretty broad based across Europe. Again, one of the important aspects of this is because this goes in -- as we talked about, into more of the biochemical markets, we've got a very strong commercial footprint in those markets already basically, the leader in biochemical screening. So we think this will be something we can penetrate relatively quickly. So it will really be more gated by the timing of, again, the tenders, more than anything else. Again, just to remind you, our plan is to have CE marked. So it will give us access to markets actually other than just Western Europe.

Okay, that's really helpful. And then apologies if you touched on this during the prepared remarks, but how did EUROIMMUN do organically during the quarter? And now that you've had a chance to sort of think about that business, what are you thinking about in terms of the time line associated with bringing that portfolio to the U.S. in a meaningful way?

So EUROIMMUN continues to do well. So if you look their results through 3 quarters, they continue to grow organically in the high-teens area. I would say they're growing in 2017 in excess of what we assumed in the model. And so one of the things we have been spending a fair amount of time on over the last several weeks is how we can be prepared to penetrate the U.S. market sort of as quickly as possible. And so that will be clearly one of the top priorities that we've identified in the collaboration and synergy discussion. So the plan would be to try and really drive growth in the U.S. relatively quickly.

Your next question comes from Derik De Bruin with Bank of America Merrill Lynch.

On the newborn screening aspect, I believe that you historically have partnered with Waters in the area of mass spec for that market. I'm just curious, does -- could you just remind us on that relationship? And I guess, has anything about that relationship sort of changed as you sort of launch your own system?

Yes, so you're right. The relationship historically was that we used the Waters mass spec in our solution. I mean fundamentally everything else that was in the solution and -- when we service our customers, we go from the filter paper to the puncher, to all the sample preparation, information to the detection information as far and then also the software and informatics. So moving forward now with the QSight, the plan would be to replace the Waters mass spec with the QSight. And so going forward, it would be exclusively 100% PerkinElmer solution.

Great. And I guess just to sort of stay on that as a follow-up. It's like how much of the market is mass spec-based versus biochemical-based -- the typical immunoassay screen-base for that market? And I'm just -- these questions are like penetration in the mass spec in that market and where -- what's the opportunity?

Are you talking about globally or China, I'm sorry.

I'm talking about globally on the -- where mass spec is on the global basis in terms of being...

Well I would say if you look outside the developed markets, mass spec is relatively small from a penetration perspective. But of course, today, the developed markets are a large piece of it. So from an opportunity perspective, I would say roughly 30% of the market today is probably covered by mass spec, and again, the current market and probably 70% is more biochemical. When you look at the opportunities going forward to expand the market, most of the emerging markets don't do mass spec today, they do just biochemical.

Your next question comes from Patrick Donnelly with Goldman Sachs.

This is Charlie Steinman on for Patrick. Just regarding OneSource, I was hoping to get a sense of any increased penetration of potential customers who hadn't outsourced before. And then also on OneSource, if you've seen any pull through on the product side from those relationships?

So on the first one, yes, we continue to see penetration of incremental customers, particularly outside the U.S. And so I think that's a good -- a significant component of the growth going forward. And on the second question is, it's sort of early days there. I think that's a more significant opportunity for us going forward. So we're hopeful as we get into sort of '18 and later, that we'll be able to get more pull-through on the PerkinElmer products.

Okay, great. And then maybe a little more of a high-level question. But -- you've had a nice acceleration on the Diagnostics side of the business, and clearly that's been a focus. Just curious what on the DAS side ramps that growth up over the next 1 or 2 years?

So I think it's a combination of things. First of all, as we've been focused on new products, so we've got to get some new products out into the marketplace. And I mentioned, I think over the last 9 months or so, we've got 11 new imaging and detection products out in the marketplace, that's one. The other thing is, I think disproportionately investing in those areas where I think we've got both greater growth opportunities and stronger competitive positions. And the ones I would specifically spike out would be food, in the pharma services area some of our imaging capabilities and then maybe, finally, the inorganic applications, like ICP and ICP-MS. So making sure we really sort of focus in those areas. And then the other area is just expanding our capabilities. I mentioned the fact that we just very recently opened up a manufacturing line in China for our DAS products. And I think locating more of our capabilities closer to our customers will allow us to be more nimble and respond more quickly. And also starting to adopt more of our products to the needs of those specific geographic regions. So I think it's those are the 3 key areas that I think we can sort of drive higher organic growth for DAS.

Your next question comes from Tycho Peterson with JPMorgan.

A couple of things. Rob, how much of the logistic shortfall came through this quarter, can you just quantify that? And then your guidance implies 2% and 5% organic against the modestly tougher comp in the fourth quarter. Maybe if you could just tell us where you're seeing improvement in trends coming out of the quarter? And what gives you confidence in hitting the fourth quarter bar?

Yes, so I think we felt like we got all, if not 95%, of the revenue that we missed in Q2, as I think I mentioned last quarter is because the majority of the shortfall was on the instrument side. I think we fell actually by the latter part of July or maybe even -- maybe it spilled into early August, we had shipped all that. So I think that was helpful to achieving our sort of the top-end of our guidance relative to this quarter. I think relative to the areas we're seeing, I think it starts off with getting the traction on the new products. And so that's driving food. I think we mentioned a couple or at least one nice win in OneSource. So I think that will help us here in the fourth quarter as we start to ramp that program up. And I think some of the things that we've got in place on the Diagnostics side. I think we'll see it on the genetic testing side, some improvements where we've got some expectations at QSight, starting to see some nice growth in the fourth quarter. So we think we've got pretty good alignment to the growth targets that we've laid out for Q4.

And low single-digit growth in industrial, I guess, seems a little bit light relative to what we saw on the PMI side. Is there room for improvement or upside on the industrial front versus...

Yes, I think there is. I mentioned before that we had a pretty tough comp in China relative to Q3. Last year, it was up high teens. So I think a little bit of that was a comp issue. But I think -- your question implies that we're seeing some recovery in the industrial end markets and we would agree with that. So I think we would be disappointed if we didn't see industrial start to pick up here, not only in Q4 but as we get into '18.

Your next question comes from Steve Beuchaw with Morgan Stanley.

First one is for Andy. Andy, I don't want to leave you out here. I wonder if, at the margin line, if you could give us a sense for the impact year-on-year from currency and from anything else inorganic, M&A or other, so we can get to an organic year-on-year margin.

I think -- maybe I'll start with EPS and then -- because I don't really have it quite cut by operating margin at that level. But from an EPS perspective, we would end the year expecting an FX headwind. And at this point in time, we expect FX to be an $0.08 tailwind. So if you look at our guidance with a midpoint of $2.88, it's about $0.08 higher than the January guidance we provided. So that obviously is a benefit. And then we've spent back quite a bit on R&D, which resulted in about $0.03, but we recovered that with the operational beat thus far. So I think all in all, FX for us for the year will be $0.08. The amount of revenue year-to-date, just for example, on the M&A side, is a little over $40 million, and it's about $0.02 in the second half, and I would think that, that will continue in the fourth quarter. The Bio and Delta acquisitions will fall out at that point though.

And sorry, is that all inclusive of...

That was all in our guidance at the beginning of the year, yes.

Okay, great. And then there's been a lot of commentary on this call, in the Q&A and in the prepared remarks, about new products, and you're going to see a lot of those coming through. In past years, at times in the -- outset of the year and over the course of the year though, you've talked about the dollar contribution from those products. I wondered if you could put those numbers on the new product flow this year. And then considering that some of these products have launched here relatively recently during the second half, I mean, how is that driving your thinking about new product contributions for 2018?

Steve, I'll take that. And that's a great question because it has been an important initiative of ours and a focus of ours. So if you look at new products, we start off the year and said we're looking at about a $50 million help from new products sort of incremental. And if you sort of track it through the year in the first quarter, we think it was in sort of the $13 million range. For the second quarter, it was about $21 million. We think the third quarter is maybe just a tad above that, maybe more like $22 million for the third quarter. So actually through the 9 months, we're now a little bit above our target of $50 million. So to your point, we feel good about the progress we're making here. And I think that ultimately is the lifeblood of our growth. The key is to make sure we're in attractive end markets and that we're bringing innovation to our customers to drive the incremental growth and so we continue to be very pleased with that. As we think about into '18, I mean, we'll give '18 guidance, obviously, sort of in the earlier part of next year, but we continue to be optimistic. And because as we get traction this year, it reinforces our confidence in, first of all, the process of how we're driving new products and just as importantly, the team. So the other aspect is over the last maybe 18 months, we have been upgrading the leadership of the organization. And it's great to see that it's making a difference.

Your next question comes from Daniel Leonard with Deutsche Bank.

So 2 questions. 2017 seems to be a bit of a reset year from an R&D as a percentage of revenue standpoint. How do you think about leverage on that line going forward? Are you thinking that will continue to go up, and you're going to continue to invest -- aggressively invest or would you get leverage beyond 2017?

No. I mean, I think when we set the targets out for the 22% operating margin a couple of years back, we targeted sort of 6%, 6.5% R&D spend. And I think year-to-date, we're at 6.3% or something like that. So I think we're pretty comfortable with that number. And when you think about it relative to product revenue, it gets you up in the sort of 7.5%, almost 8% area. So I think we're fine here now. Of course, with EUROIMMUN coming into the company, they do spend more as a percentage of R&D. So you will see, in fact, our R&D percentage go up. But I think that's just sort of a math exercise with EUROIMMUN coming in. But I think for the -- I'll call it the historical PerkinElmer portfolio, I think where we are now seems pretty good relative to our ability to invest in the areas that we think are important and drive the organic growth that we've talked about.

And just to kind of expand on it a little bit, we have a framework and a road map to get to the 22% by 2020. And it's really -- it's a combination of R&D investment, but it's also some of the gross margin expansion efforts that Rob discussed as well as the accelerated organic growth from some of our R&D investments. And we still think that we have room to really leverage SG&A. So I think we're right in line, as Rob said. And I think we're able to make those investments and still achieve our longer-term goal.

Okay. And then just one follow-up question. So I'm trying to understand all the pluses and minuses on the top line, and it sounds you're coming in better in 2017 year-to-date on new products and that's a good guide. But year-to-date organic growth, it's about 3 points. What are the offsets? Is it something besides rads? Is maybe newborn screening a bad guy and that can turn into a good guy in 2018? What color can you offer there?

No, I don't think there's any bad guys in Diagnostics right now. And generally, we feel like Diagnostics is on track to do the sort of 6% or 7% organic that we talked about in the beginning of the year. I think the offsets are in the areas where we haven't sort of invested in the new products within DAS. So we've talked a fair amount about the organic portfolios. So ICP, ICP-MS, even AA. I think the areas that, hopefully, we'll be able to focus more on in 2018 are in areas like some of the chromatography areas, some of the areas around thermal and material characterization. So I think there are some areas where we're probably not making the progress -- we're not growing with the market because, again, we focus some of our investments in some of those other areas that support the food area or support pharma, et cetera.

Your next question comes from Emily Stent with Robert W. Baird.

First off, looking at the pharma end market. Can you break out how much growth you saw from capital equipment versus recurring revenue?

I would say, if we include in recurring services, that would be basically the majority of the growth. I would say on a product basis, we were relatively flat. When you look at things like high-content imaging doing well and a couple of other imaging products being offset by radiometric detection and sort of drug discovery. So the product was relatively flat, services was the majority of the growth.

Okay, that makes sense. And then with Andy set to retire next August, how has the CFO replacement search been going? And when should we expect to hear an update?

I'll start out by saying it's going to be impossible to replace Andy. So -- but having said that, it's going well. I mean, it's early days. We've hired a search firm, we've seen some preliminary lists of very qualified candidates. And so I think we feel pretty good about the ability to get a very strong person in here. I think the nice thing is, because of Andy's willingness to give us a fair amount of time, I think we should be in good shape as we get into sort of middle part of '18.

Your next question comes from Jack Meehan with Barclays.

Wanted to focus on the growth in the food end market. So I think I caught 20% in the prepared remarks. I think it was expected to swing into the teens, but that would be a little better than we're looking for? Maybe just elaborate on the trends you're seeing there.

Yes. So we continue to see strong growth in China, which is probably expected. We saw particularly strength in Europe this quarter, very strong growth. And I think we just continue -- I think it's a combination of -- we bought Perten, we bought Delta, we bought Bioo, and we've been in the process of trying to get those integrated. And then also leveraging some of the channel -- historical channels of PerkinElmer. And it sort of takes some time to do that, and I think we're starting to see some nice traction there. And we're getting into some of the larger food customers. And once we're in there, we'll be able to leverage additional products. So either PerkinElmer products are pulling Perkin and Delta through or vice versa.

Do you think double-digit growth can sustain into the fourth quarter and maybe into '18?

I would say, we target food as sort of high single. I think in given quarters, we could probably see something in the teens. But I would say built into our Q4 guide is food in the sort of low double-digit range.

And I'm showing no further questions at this time. I'd like to turn the call back over to Mr. Rob Friel for closing remarks.

Great. Well first of all, we appreciate your questions. And again, we feel good about our financial performance year-to-date as well as the progress we continue to make on our strategic priorities.

Thank you for your interest in PerkinElmer and have a great evening.

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you all may disconnect. Everyone, have a wonderful day.